Genetic engineering
Animal science firm Recombinetics adds board members, nears $10M investment
Recombinetics, the St. Paul-based "gene-editing" company, is starting to scale up.
Dr. Scott Fahrenkrug, the University of Minnesota researcher and founder, has moved from CEO to chairman of the board and chief scientific officer.
Ian Friendly, 55, a 30-year General Mills veteran, and most recently chief operating officer, has signed on as chief executive.
Tammy Lee Stanoch, 45, a government relations and marketing veteran of Carlson and the former Northwest Airlines, has signed on as chief corporate affairs officer.
Friendly said last week that the company is closing in on a $10 million round of equity capital — raised from individual investors, mostly Minnesotans.
"We've had some breakthroughs in technology and developments in animal welfare in agriculture and biomedical research," Friendly said, adding the firm will have revenue approaching $1 million this year. "We're ready with products. Now we have to get the other functions ready.
"In three years, we hope to be a public company. There might also be a strategic buyer, but we're more interested in being an independent company that controls our own destiny. We think, once the flywheel starts turning, the company can grow quickly. Our value is probably as much in IP and royalty [to other companies] as commercial sales."
The company also has appointed six new board members, including Mitch Abrahamsen, senior vice president of research at Cobb-Vantress, Wendell King, a consultant and former Medtronic vice president; and Mark Kroll, the former chief technology officer at St. Jude Medical.